Topical treatments for eczema and dermatitis
Pro Research Analysisby 
Searched over 200M research papers
Topical Pharmacological Treatments for Eczema and Dermatitis
Topical corticosteroids (TCS) remain the mainstay of treatment for eczema and dermatitis, especially for managing flare-ups. Moderate and potent TCS are generally more effective than mild TCS, particularly in moderate to severe cases, and are associated with a low risk of skin thinning when used short-term. There is little evidence that very potent TCS are more effective than potent TCS, and once-daily application is usually as effective as twice-daily use. Proactive, intermittent use of TCS (such as weekend therapy) can help prevent relapses and is more effective than reactive use alone. However, the risk of skin thinning increases with higher potency and longer-term use, so careful monitoring is recommended 1356+4 MORE.
Topical calcineurin inhibitors (TCIs), such as tacrolimus and pimecrolimus, are effective alternatives to corticosteroids, especially for sensitive areas like the face and skin folds. High-dose tacrolimus (0.1%) and pimecrolimus are among the most effective non-steroidal options for improving symptoms and maintaining disease control. TCIs are also useful for proactive therapy to prevent flares. However, they are more likely than TCS to cause local application-site reactions, such as burning or stinging 1356+3 MORE.
Other topical anti-inflammatory agents, such as Janus kinase (JAK) inhibitors (e.g., ruxolitinib, delgocitinib) and phosphodiesterase-4 (PDE-4) inhibitors (e.g., crisaborole, difamilast), are newer options. JAK inhibitors and potent TCS are consistently ranked among the most effective, while PDE-4 inhibitors are generally less effective. Local site reactions are more common with crisaborole and TCIs than with TCS. There is no evidence of increased skin thinning with short-term use of TCS, but longer-term use may increase this risk 13.
Topical antibiotics, whether used alone or in combination, are among the least effective treatments for eczema and are generally not recommended unless there is clear evidence of secondary infection 1356+3 MORE.
Non-Pharmacological Topical Treatments: Emollients, Cleansers, and Barrier Creams
Non-pharmacological topical treatments, such as emollients, cleansers, and barrier creams, are essential for all patients with eczema and dermatitis. These products help repair and maintain the skin barrier, reduce dryness, and prevent flare-ups. Regular and liberal use of emollients is recommended as the foundation of maintenance therapy. Soap-free cleansers are preferred to avoid further irritation and barrier disruption. Barrier creams can provide additional protection, especially in hand eczema and occupational dermatitis 2456+3 MORE.
Phytochemical-Based and Natural Topical Treatments
Recent advances in phytochemical-based topical applications, including plant extracts and bioactive compounds, show promise in managing eczema. These natural treatments may help reduce inflammation, improve skin barrier function, and alleviate symptoms such as itching and dryness. Various carriers, such as liposomes and nanoparticles, are being explored to enhance the delivery and effectiveness of these agents. Phytochemical-based treatments may also reduce the risk of long-term side effects associated with conventional topical drugs, but more research is needed to confirm their efficacy and safety .
Special Considerations and Adjunctive Therapies
Topical treatments should be tailored to the individual, considering disease severity, location, and patient age. In addition to pharmacological and non-pharmacological topical therapies, adjunctive measures such as UV phototherapy, psychosomatic counseling, and patient education programs ("eczema school") can be beneficial. Systemic treatments are reserved for severe, refractory cases. Antimicrobial therapy is only indicated for secondary infections, and oral antihistamines are generally not effective for itch control in eczema 5678+1 MORE.
Conclusion
The most effective topical treatments for eczema and dermatitis are moderate to potent topical corticosteroids and topical calcineurin inhibitors, with newer agents like JAK inhibitors also showing promise. Emollients and barrier repair products are essential for all patients. Treatment should be individualized, balancing efficacy, safety, and patient preference, with regular monitoring for potential side effects. Emerging natural and phytochemical-based therapies may offer additional options in the future, but require further study.
Sources and full results
Most relevant research papers on this topic